-
Biogen VALOR study (APPROVED)
The VALOR Study is evaluating the safety and potential efficacy of an investigational drug BIIB067 for people with ALS with a SOD1 gene mutation. More >>
-
Apellis APL2-ALS-206 trial (STOP ALS DEVELOPMENT)
In collaboration with our academic partner TRICALS, Apellis is conducting a Phase 2 trial to determine the safety and efficacy of their investigational drug pegcetacoplan for the treatment of ALS.… More >>
-
Cytokinetics COURAGE-ALS trial (STOP ALS DEVELOPMENT)
In collaboration with our academic partner TRICALS, Cytokinetics is conducting a Phase 3 trial to determine the safety and efficacy of their investigational drug reldesemtiv for the treatment of ALS.… More >>
-
Amylyx PHOENIX trial (STOP ALS DEVELOPMENT)
In collaboration with our academic partner TRICALS, Amylyx Pharmaceuticals is conducting a Phase 3 trial to determine the safety and efficacy of their investigational drug ‘AMX0035’ for the treatment of… More >>
-
Ferrer ADORE trial (STOP STUDY)
In collaboration with our academic partner TRICALS, Ferrer is conducting a Phase 3 trial to evaluate the safety and potential efficacy of the investigational drug FNP122 for people with ALS.… More >>
-
MAGNET study (RECRUITING)
Lithium carbonate in pALS with UNC13A variation The MAGNET study is an innovative clinical research platform investigating multiple potential ALS medicines simultaneously. Thisapproach will significantly enhance the number of patients… More >>
-
Novartis ASTRALS trial (RECRUITING)
A phase 2, double-blind randomised placebo-controlled parallel-group study of VHB937 in amyotrophic lateral sclerosis (ALS) for 40 weeks followed by open-label extension. The sponsor of the study is Novartis Pharma… More >>
-
Argenx reALiSe trial (ACTIVE)
In the reALiSe study the safety and efficacy of the drug ARGX-119 for the treatment of ALS isinvestigated. Furthermore, the study investigates how the body and immune system reactsto ARGX-119.… More >>
